Expo Hub
Susan’s theranostics
journey
Follow Susan on her neuroendocrine tumors journey
1National Cancer Institute (NCI). Neuroendocrine Tumor (NET). Available at www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-endocrine-tumor/carcinoid-tumor.
2Data courtesy of Rome Imaging Center, Rome, Georgia, USA.
3Products and features mentioned herein are not commercially available in all countries. Future availability cannot be guaranteed.
4Data courtesy of Osaka City University Hospital, Osaka, Japan.
5Novartis. Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors. Available at https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors.
6Every Symbia Pro.specta configuration produces the highest image quality in its class. Based on competitive literature available at time of publication. Data on file.
7Data courtesy of United Theranostics, Glenburnie, Maryland, USA.